A detailed history of Prelude Capital Management, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 28,955 shares of APLS stock, worth $839,984. This represents 0.05% of its overall portfolio holdings.

Number of Shares
28,955
Previous 28,955 -0.0%
Holding current value
$839,984
Previous $835,000 -0.0%
% of portfolio
0.05%
Previous 0.03%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$28.84 - $41.15 $462,045 - $659,264
16,021 Added 123.87%
28,955 $835,000
Q2 2024

Aug 14, 2024

BUY
$38.07 - $59.71 $492,397 - $772,289
12,934 New
12,934 $496,000
Q4 2023

Feb 14, 2024

BUY
$37.14 - $64.82 $306,033 - $534,116
8,240 New
8,240 $493,000
Q2 2023

Aug 14, 2023

BUY
$76.68 - $93.31 $219,381 - $266,959
2,861 New
2,861 $260,000
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $505,474 - $786,670
11,293 New
11,293 $771,000
Q3 2021

Nov 15, 2021

SELL
$31.4 - $69.84 $139,227 - $309,670
-4,434 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$40.9 - $64.9 $448,141 - $711,109
-10,957 Reduced 71.19%
4,434 $280,000
Q1 2021

May 17, 2021

BUY
$40.8 - $57.39 $627,952 - $883,289
15,391 New
15,391 $660,000
Q3 2020

Nov 16, 2020

SELL
$25.89 - $33.65 $102,420 - $133,119
-3,956 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$24.8 - $38.49 $11,110 - $17,243
448 Added 12.77%
3,956 $129,000
Q1 2020

May 15, 2020

BUY
$17.91 - $44.33 $62,828 - $155,509
3,508 New
3,508 $94,000
Q1 2019

May 15, 2019

SELL
$12.81 - $19.82 $151,029 - $233,677
-11,790 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$11.47 - $18.71 $135,231 - $220,590
11,790 New
11,790 $156,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.19B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.